First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

Condition(s) studied

Investigational drug(s) / intervention(s)

Pulmonary vein isolation: Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation

dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™: Antiarrhythmic drugs

Study summary

The goal of this multicentre, prospective, randomized, open, blinded for evaluation of end point (PROBE) controlled parallel-group superiority trial, is to compare the efficacy of antiarrhythmic drug (AAD) therapy and cryoballoon pulmonary vein isolation (PVI) regarding freedom from atrial fibrillation (%) assessed by an implantable cardiac monitor (ICM), ECG tracing or Holter at 12 months in patients with persistent AF. The main question\[s\] it aims to answer are:

* Will first-line cryoballoon ablation for PVI compared to AAD, result in 25 % higher freedom from atrial tachyarrhythmias lasting \> 6 minutes at 12 months (primary outcome) excluding three months initial blanking period, in patients with symptomatic and recurrent persistent AF?
* Will first-line cryoablation for PVI, compared to AAD result in a superior improvement in health related Quality of Life (HRQoL), AF/AT burden, AF/AT progression and reversion, more reverse atrial remodeling, cognitive function, healthcare utilization with associated costs, better safety, at 12-24-36 months as compared with drug use? Participants will be randomized 1:1 to first-line PVI using the cryoballoon or to first-line antiarrhythmic drug therapy and during 3 years follow-up undergo regular;

* Continuous ECG monitoring for assessment of first AF recurrence and AF burden using an implantable cardiac monitor,
* Regular echocardiographic exams for reverse atrial remodelling assessment,
* HRQoL questionnaires
* Assessment of cognitive function
* Atrial fibrillation evaluation regarding structured characterisation and AF progression/regression
* Assessment of Health care use and costs
* Safety

Eligibility

Primary outcome measure(s)

• Proportion of patients free from first atrial tachyarrhythmia recurrence lasting 6 minutes or longer — 12 months after initiation of allocated treatment excluding the first 3 months blanking period
  In the absence of antiarrhythmic drugs in ablation group as documented by an implantable cardiac monitor from initiation of treatment.

Trial sites (6)

More Region Örebro County trials in Sweden

Other trials for the same condition